Table 3.
Baseline clinicopathological characteristics according to HER2 status of 207 HR− BC patients
| Clinicopathological characteristics | Overall (N = 207, %) | HER2-null (24, 11.6%) | HER2 (75, 36.2%) | HER2-low (108, 52.2%) | P (HER2 status) | |
|---|---|---|---|---|---|---|
| Null vs ultra-low | Ultra-low vs low | |||||
| Age/years | ||||||
| Median/range | 54/28–84 | 52/30–76 | 52/28–78 | 55/31–84 | 0.828* | 0.013* |
| Mean ± SD | 53.2 ± 10.9 | 50.1 ± 11.3 | 51.2 ± 11.0 | 55.2 ± 10.5 | ||
| Menopaual status | ||||||
| Pre/perimenopausal | 115 (55.6) | 15 (62.5) | 47 (62.7) | 53 (49.1) | 0.988 | 0.069 |
| Postmenopausal | 92 (44.4) | 9 (37.5) | 28 (37.3) | 55 (50.9) | ||
| Breast position | ||||||
| Left | 115 (55.6) | 15 (62.5) | 45 (60.0) | 55 (50.9) | 0.827 | 0.225 |
| Right | 92 (44.4) | 9 (37.5) | 30 (40.0) | 53 (49.1) | ||
| Tumor size/cm | ||||||
| Median/range | 2.3/0.3–10 | 2.0/0.8–3.3 | 2.2/0.5–7.5 | 2.5/0.3–10 | 0.176* | 0.121* |
| Mean ± SD | 2.5 ± 1.2 | 2.0 ± 0.5 | 2.4 ± 1.1 | 2.6 ± 1.3 | ||
| Tumor multiplicity | ||||||
| Single | 190 (91.8) | 24 (1.0) | 68 (90.7) | 98 (90.7) | 0.190 | 0.986 |
| Multiple | 17 (8.2) | 0 (0.0) | 7 (9.3) | 10 (9.3) | ||
| Histologic type | ||||||
| Ductal | 161 (77.8) | 19 (79.2) | 61 (81.3) | 81 (75.0) | 0.797 | 0.556 |
| Lobular | 4 (1.9) | 0 (0.0) | 1 (1.3) | 3 (2.8) | ||
| Other | 42 (20.3) | 5 (20.8) | 13 (17.4) | 24 (22.2) | ||
| Grade | ||||||
| 1 | 1 (0.5) | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0.804 | 0.035 |
| 2 | 38 (18.4) | 3 (12.5) | 8 (10.7) | 27 (25.0) | ||
| 3 | 168 (81.1) | 21 (87.5) | 61 (81.3) | 80 (74.1) | ||
| pT | ||||||
| 1 | 87 (42.0) | 14 (58.3) | 35 (46.7) | 38 (35.2) | 0.486 | 0.270 |
| 2 | 113 (54.6) | 10 (41.7) | 38 (50.7) | 65 (60.2) | ||
| 3 | 7 (3.4) | 0 (0.0) | 2 (2.6) | 5 (4.6) | ||
| pN | ||||||
| 0 | 41 (19.8) | 5 (20.8) | 17 (22.7) | 19 (17.6) | 0.985 | 0.266 |
| 1 | 25 (12.1) | 2 (8.3) | 6 (8.0) | 17 (15.7) | ||
| 2 | 7 (3.4) | 0 (0.0) | 1 (1.3) | 6 (5.6) | ||
| 3 | 9 (4.3) | 1 (4.2) | 3 (4.0) | 5 (4.6) | ||
| Unknown | 125 (60.4) | 16 (66.7) | 48 (64.0) | 61 (56.5) | ||
| Ki67 | ||||||
| Median/range | 2/1–90 | 16/1–90 | 2/1–90 | 2/1–80 | 0.791* | 0.003* |
| Mean ± SD | 23.1 ± 30.0 | 31.8 ± 32.6 | 30.0 ± 32.3 | 16.7 ± 25.9 | ||
| TILs | ||||||
| Median/range | 15/1–90 | 10/1–80 | 20/1–90 | 15/1–90 | 0.488* | 0.786* |
| Mean ± SD | 22.7 ± 20.9 | 20.0 ± 25.8 | 23.5 ± 20.8 | 22.7 ± 20.0 | ||
| Unknown | 3 | 0 | 0 | 3 | ||
| Type of surgery | ||||||
| BCS/+BR | 51 (24.6) | 8 (33.3) | 19 (25.4) | 24 (22.2) | 0.746 | 0.408 |
| Mastectomy | 69 (33.4) | 8 (33.3) | 28 (37.3) | 33 (30.6) | ||
| Mastectomy + ALND | 87 (42.0) | 8 (33.3) | 28 (37.3) | 51 (47.2) | ||
| Recurrence or metastasis | ||||||
| Yes | 16 (7.7) | 3 (12.5) | 2 (2.7) | 10 (9.3) | 0.090 | 0.126 |
| No | 191 (92.3) | 21 (87.5) | 73 (97.3) | 98 (90.7) | ||
| Postoperative chemotherapy | ||||||
| Yes | 198 (95.7) | 23 (95.8) | 72 (96.0) | 103 (95.4) | 1.000 | 1.000 |
| No | 9 (4.3) | 1 (4.2) | 3 (4.0) | 5 (4.6) | ||
| Postoperative radiotherapy | ||||||
| Yes | 34 (16.4) | 4 (16.7) | 12 (16.0) | 18 (16,7) | 1.000 | 0.905 |
| No | 173 (83.6) | 20 (83.3) | 63 (84.0) | 63 (58.3) | ||
BC breast cancer; HR hormone receptor; TILS tumor infiltrating lymphocytes; BCS breast-conserving surgery; BR breast reconstruction; ALND axillary lymph node dissection; SD standard deviation
Bold indicates P < 0.05
*T-test; other testing methods are Chi-square test or Fisher’s exact test